AhR ligand Aminoflavone inhibits α6-integrin expression and breast cancer sphere-initiating capacity

Cancer Letters

Volumn 376, Issue 1, 2016, Pages 53-61

  Brantley, Eileen ^a   Callero, Mariana A ^b   Berardi, Damian E ^b   Campbell, Petreena ^a   Rowland, Leah ^a   Zylstra, Dain ^a   Amis, Louisa ^a   Yee, Michael ^c   Simian, Marina ^b,d   Todaro, Laura ^b   Loaiza Perez, Andrea I ^b   Soto, Ubaldo ^a  

^a LOMA LINDA UNIVERSITY HEALTH   (United States)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSIDAD NACIONAL DE SAN MARTÍN   (Argentina)

Author keywords

Aminoflavone; Aryl hydrocarbon receptor; Mammospheres; 6 integrin

Indexed keywords

AFP 464; ALPHA6 INTEGRIN; AMINOFLAVONE; AROMATIC HYDROCARBON RECEPTOR; TRANSCRIPTION FACTOR FRA 1; UNCLASSIFIED DRUG; AHR PROTEIN, HUMAN; AHR PROTEIN, MOUSE; ANTINEOPLASTIC AGENT; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; FLAVONOID; ITGA6 PROTEIN, HUMAN; LIGAND; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CELLULAR PARAMETERS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MAMMOSPHERE; MCF 7 CELL LINE; MDA MB 231 CELL LINE; MOUSE; MOUSE MODEL; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; ACTIVE TRANSPORT; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CANCER STEM CELL; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; GENETICS; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELL LINE; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; TIME FACTOR;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BREAST NEOPLASMS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHA6; LIGANDS; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE, INBRED BALB C; NEOPLASTIC STEM CELLS; PHENOTYPE; PRODRUGS; RECEPTORS, ARYL HYDROCARBON; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TIME FACTORS;

EID: 84961720615     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.03.025     Document Type: Article

References (65)

1. Mitra A., Mishra L., Li S. EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 2015, 6:10697-10711.
2. Kwon M.J. Emerging roles of claudins in human cancer. Int. J. Mol. Sci 2013, 14:18148-18180.
3. Gong C., Yao H., Liu Q., Chen J., Shi J., Su F., et al. Markers of tumor-initiating cells predict chemoresistance in breast cancer. PLoS ONE 2010, 5:e15630.
4. Morrison B.J., Schmidt C.W., Lakhani S.R., Reynolds B.A., Lopez J.A. Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res 2008, 10:210.
5. Ghebeh H., Sleiman G.M., Manogaran P.S., Al-Mazrou A., Barhoush E., Al-Mohanna F.H., et al. Profiling of normal and malignant breast tissue show CD44high/CD24low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers. BMC Cancer 2013, 13:289.
6. Feifei N., Mingzhi Z., Yanyun Z., Huanle Z., Fang R., Mingzhu H., et al. MicroRNA expression analysis of mammospheres cultured from human breast cancers. J. Cancer Res. Clin. Oncol 2012, 138:1937-1944.
7. Grimshaw M.J., Cooper L., Papazisis K., Coleman J.A., Bohnenkamp H.R., Chiapero-Stanke L., et al. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res 2008, 10:R52.
8. Seguin L., Desgrosellier J.S., Weis S.M., Cheresh D.A. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol 2015, 25:234-240.
9. Marthick J.R., Dickinson J.L. Emerging putative biomarkers: the role of alpha 2 and 6 integrins in susceptibility, treatment, and prognosis. Prostate Cancer 2012, 2012:298732.
10. Wang Y., Shenouda S., Baranwal S., Rathinam R., Jain P., Bao L., et al. Integrin subunits alpha5 and alpha6 regulate cell cycle by modulating the chk1 and Rb/E2F pathways to affect breast cancer metastasis. Mol. Cancer 2011, 10:84.
11. Friedrichs K., Ruiz P., Franke F., Gille I., Terpe H.J., Imhof B.A. High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res 1995, 55:901-906.
12. Cariati M., Naderi A., Brown J.P., Smalley M.J., Pinder S.E., Caldas C., et al. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int. J. Cancer 2008, 122:298-304.
13. Keller P.J., Lin A.F., Arendt L.M., Klebba I., Jones A.D., Rudnick J.A., et al. Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines. Breast Cancer Res 2010, 12:R87.
14. Meyer M.J., Fleming J.M., Lin A.F., Hussnain S.A., Ginsburg E., Vonderhaar B.K. CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res 2010, 70:4624-4633.
15. Zhao S., Kanno Y., Nakayama M., Makimura M., Ohara S., Inouye Y. Activation of the aryl hydrocarbon receptor represses mammosphere formation in MCF-7 cells. Cancer Lett 2012, 317:192-198.
16. Prud'homme G.J., Glinka Y., Toulina A., Ace O., Subramaniam V., Jothy S. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS ONE 2010, 5:e13831.
17. Feng S., Cao Z., Wang X. Role of aryl hydrocarbon receptor in cancer. Biochim. Biophys. Acta 2013, 1836:197-210.
18. Loaiza-Perez A.I., Kenney S., Boswell J., Hollingshead M., Alley M.C., Hose C., et al. Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol. Cancer Ther 2004, 3:715-725.
19. Stark K., Burger A., Wu J., Shelton P., Polin L., Li J. Reactivation of estrogen receptor alpha by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor. PLoS ONE 2013, 8:e74525.
20. McLean L., Soto U., Agama K., Francis J., Jimenez R., Pommier Y., et al. Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells. Int. J. Cancer 2008, 122:1665-1674.
21. Ciolino H.P., Dankwah M., Yeh G.C. Resistance of MCF-7 cells to dimethylbenz(a)anthracene-induced apoptosis is due to reduced CYP1A1 expression. Int. J. Oncol 2002, 21:385-391.
22. Pontiggia O., Sampayo R., Raffo D., Motter A., Xu R., Bissell M.J., et al. The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin. Breast Cancer Res. Treat 2012, 133:459-471.
23. Callero M.A., Suarez G.V., Luzzani G., Itkin B., Nguyen B., Loaiza-Perez A.I. Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment. Int. J. Oncol 2012, 41:125-134.
24. Walzl A., Unger C., Kramer N., Unterleuthner D., Scherzer M., Hengstschlager M., et al. The resazurin reduction assay can distinguish cytotoxic from cytostatic compounds in spheroid screening assays. J. Biomol. Screen 2014, 19:1047-1059.
25. van Riggelen J., Buchwalter G., Soto U., De-Castro Arce J., zur Hausen H., Wasylyk B., et al. Loss of net as repressor leads to constitutive increased c-fos transcription in cervical cancer cells. J. Biol. Chem 2005, 280:3286-3294.
26. Pontiggia O., Rodriguez V., Fabris V., Raffo D., Bumaschny V., Fiszman G., et al. Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions. Breast Cancer Res. Treat 2009, 116:247-255.
27. Simian M., Manzur T., Rodriguez V., de Kier Joffe E.B., Klein S. A spontaneous estrogen dependent, tamoxifen sensitive mouse mammary tumor: a new model system to study hormone-responsiveness in immune competent mice. Breast Cancer Res. Treat 2009, 113:1-8.
28. Raffo D., Berardi D.E., Pontiggia O., Todaro L., de Kier Joffe E.B., Simian M. Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate. Breast Cancer Res. Treat 2013, 142:537-548.
29. Hutchinson I., Chua M.S., Browne H.L., Trapani V., Bradshaw T.D., Westwell A.D., et al. Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J. Med. Chem 2001, 44:1446-1455.
30. Barbieri F., Wurth R., Ratto A., Campanella C., Vito G., Thellung S., et al. Isolation of stem-like cells from spontaneous feline mammary carcinomas: phenotypic characterization and tumorigenic potential. Exp. Cell Res 2012, 318:847-860.
31. Taddei I., Deugnier M.A., Faraldo M.M., Petit V., Bouvard D., Medina D., et al. Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat. Cell Biol 2008, 10:716-722.
32. Alexander C.M. Base behavior behind budding breasts: integrins and mammary stem cell activity. Cell Stem Cell 2008, 3:5-6.
33. Gonzalez A.M., Gonzales M., Herron G.S., Nagavarapu U., Hopkinson S.B., Tsuruta D., et al. Complex interactions between the laminin alpha 4 subunit and integrins regulate endothelial cell behavior in vitro and angiogenesis in vivo. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:16075-16080.
34. Timmer A., Oosterhuis J.W., Schraffordt Koops H., Sleijfer D.T., Szabo B.G., Timens W. The tumor microenvironment: possible role of integrins and the extracellular matrix in tumor biological behavior of intratubular germ cell neoplasia and testicular seminomas. Am. J. Pathol 1994, 144:1035-1044.
35. Nass S.J., Dickson R.B. Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res. Treat 1997, 44:1-22.
36. Nishida K., Kitazawa R., Mizuno K., Maeda S., Kitazawa S. Identification of regulatory elements of human alpha 6 integrin subunit gene. Biochem. Biophys. Res. Commun 1997, 241:258-263.
37. Lu D., Chen S., Tan X., Li N., Liu C., Li Z., et al. Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy. Cancer Res 2012, 72:3451-3456.
38. Callero M.A., Loaiza-Perez A.I. The role of aryl hydrocarbon receptor and crosstalk with estrogen receptor in response of breast cancer cells to the novel antitumor agents benzothiazoles and aminoflavone. Int. J. Breast Cancer 2011, 2011:923250.
39. Raffo D., Pontiggia O., Bal de Kier Joffe E., Simian M. Non-genomic actions of estradiol and 4-OH-tamoxifen on murine breast cancer cells. Oncol. Rep 2015, 33:439-447.
40. Fiorillo M., Verre A.F., Iliut M., Peiris-Pages M., Ozsvari B., Gandara R., et al. Graphene oxide selectively targets cancer stem cells, across multiple tumor types: implications for non-toxic cancer treatment, via "differentiation-based nano-therapy". Oncotarget 2015, 6(6):3553-3562.
41. Takehara M., Hoshino T., Namba T., Yamakawa N., Mizushima T. Acetaminophen-induced differentiation of human breast cancer stem cells and inhibition of tumor xenograft growth in mice. Biochem. Pharmacol 2011, 81:1124-1135.
42. Hebbard L., Cecena G., Golas J., Sawada J., Ellies L.G., Charbono A., et al. Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene 2011, 30:301-312.
43. Li C.I. Risk of mortality by histologic type of breast cancer in the United States. Horm. Cancer 2010, 1:156-165.
44. Croker A.K., Allan A.L. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44(+) human breast cancer cells. Breast Cancer Res. Treat 2012, 133:75-87.
45. Shackleton M., Vaillant F., Simpson K.J., Stingl J., Smyth G.K., Asselin-Labat M.L., et al. Generation of a functional mammary gland from a single stem cell. Nature 2006, 439:84-88.
46. Zhang M., Behbod F., Atkinson R.L., Landis M.D., Kittrell F., Edwards D., et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008, 68:4674-4682.
47. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst 2008, 100:672-679.
48. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:13820-13825.
49. Soo J.S., Ng C.H., Tan S.H., Malik R.A., Teh Y.C., Tan B.S., et al. Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells. Apoptosis 2015, 20:1373-1387.
50. Liu P., Kumar I.S., Brown S., Kannappan V., Tawari P.E., Tang J.Z., et al. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br. J. Cancer 2013, 109:1876-1885.
51. Chai F., Zhou J., Chen C., Xie S., Chen X., Su P., et al. The Hedgehog inhibitor cyclopamine antagonizes chemoresistance of breast cancer cells. Onco Targets Ther 2013, 6:1643-1647.
52. Meng L.H., Meng Z., Miao Z.H., Veenstra T.D., Pommier Y. Cytokeratin-RNA cross-linking mediated by the antitumor aminoflavone, 5-amino-2,3-fluorophenyl-6,8-difluoro-7-methyl-4H-1-benzopyran-4-one. J. Pharmacol. Exp. Ther 2008, 325:674-680.
53. Kuffel M.J., Schroeder J.C., Pobst L.J., Naylor S., Reid J.M., Kaufmann S.H., et al. Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol. Pharmacol 2002, 62:143-153.
54. Landowski T.H., Gard J., Pond E., Pond G.D., Nagle R.B., Geffre C.P., et al. Targeting integrin alpha6 stimulates curative-type bone metastasis lesions in a xenograft model. Mol. Cancer Ther 2014, 13:1558-1566.
55. Zhao S., Ohara S., Kanno Y., Midorikawa Y., Nakayama M., Makimura M., et al. HER2 overexpression-mediated inflammatory signaling enhances mammosphere formation through up-regulation of aryl hydrocarbon receptor transcription. Cancer Lett 2013, 330:41-48.
56. Cattavarayane S., Palovuori R., Tanjore Ramanathan J., Manninen A. alpha6beta1- and alphaV-integrins are required for long-term self-renewal of murine embryonic stem cells in the absence of LIF. BMC Cell Biol 2015, 16:3.
57. Hayashi Y., Furue M.K., Okamoto T., Ohnuma K., Myoishi Y., Fukuhara Y., et al. Integrins regulate mouse embryonic stem cell self-renewal. Stem Cells 2007, 25:3005-3015.
58. Li N., Zhang Y., Naylor M.J., Schatzmann F., Maurer F., Wintermantel T., et al. Beta1 integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli. EMBO J. 2005, 24:1942-1953.
59. Hiscox S., Jiang W.G., Obermeier K., Taylor K., Morgan L., Burmi R., et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int. J. Cancer 2006, 118:290-301.
60. Xie G., Ji A., Yuan Q., Jin Z., Yuan Y., Ren C., et al. Tumour-initiating capacity is independent of epithelial-mesenchymal transition status in breast cancer cell lines. Br. J. Cancer 2014, 110:2514-2523.
61. Song Y., Song S., Zhang D., Zhang Y., Chen L., Qian L., et al. An association of a simultaneous nuclear and cytoplasmic localization of Fra-1 with breast malignancy. BMC Cancer 2006, 6:298.
62. Jambal P., Badtke M.M., Harrell J.C., Borges V.F., Post M.D., Sollender G.E., et al. Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Breast Cancer Res. Treat 2013, 137:431-448.
63. Velcich A., Yang W., Heyer J., Fragale A., Nicholas C., Viani S., et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002, 295:1726-1729.
64. Adsay N.V., Merati K., Nassar H., Shia J., Sarkar F., Pierson C.R., et al. Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas. Am. J. Surg. Pathol 2003, 27:571-578.
65. Swanson H.I., Njar V.C., Yu Z., Castro D.J., Gonzalez F.J., Williams D.E., et al. Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metab. Dispos 2010, 38:539-544.